ストックスクリーナーアプリを入手
47.99
0.93%
-0.45
アフターアワーズ：
47.99
前日終値:
$48.44
開ける：
$48.54
24時間の取引高:
891.56K
Relative Volume:
0.51
時価総額：
$4.73B
収益：
$4.10M
当期純損益:
$-568.53M
株価収益率:
-7.7256
EPS:
-6.2118
ネットキャッシュフロー:
$-401.18M
1週間 パフォーマンス:
+3.12%
1か月 パフォーマンス:
-12.01%
6か月 パフォーマンス:
-3.94%
1年 パフォーマンス:
-14.70%
1日の値動き範囲:
$47.31
$49.03
1週間の範囲:
$45.89
$49.03
52週間の値動き範囲:
$44.12
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Compare CRSP vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
47.99 | 4.60B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | JP Morgan | Overweight |
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance UK
CRSP|CRISPR Therapeutics AG|Price:46.770|Chg%:+0.230 - TradingKey
BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics - Stock Titan
CRISPR Therapeutics AG (CRSP) Cash Flow - TradingKey
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close. - The Motley Fool
CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990 - TradingKey
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
TradingKey - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Affinity Asset Advisors LLC Buys Shares of 150,000 CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T - Sahm
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
KBC Group NV Acquires 113,997 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
CRISPR Therapeutics (CRSP) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary - Quartr
CRISPR Therapeutics (CRSP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary - Quartr
Monashee Investment Management LLC Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Receives a Hold from Goldman Sachs - The Globe and Mail
CRSP: CRISPR Therapeutics AG Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Citizens reiterates CRISPR Therapeutics stock rating on pipeline progress - Investing.com
Citizens reiterates CRISPR Therapeutics stock rating on pipeline progress By Investing.com - Investing.com UK
US226712AA5 Bond Profile — Key Metrics - TradingView
CRISPR Therapeutics AG (CRSP) declines more than market: Some information for investors - MSN
CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
CRISPR Therapeutics: A Catalyst-Rich 12 Months Ahead (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics stock trades steady as gene-editing pipeline advances after quarterly loss narro - AD HOC NEWS
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - ADVFN
Nwam LLC Sells 52,670 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued? - Yahoo Finance UK
Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path? - Yahoo Finance
(CRSP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
CRISPR Therapeutics (CRSP) Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns - simplywall.st
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance
CRISPR Therapeutics (CRSP) Slides For Six Days, Is The Stock Now Cheap? - Yahoo Finance
Is CRISPR Therapeutics (CRSP) Near Fair Value With $2.4B In Cash? - Sahm
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market - Yahoo Finance
Citigroup Maintains CRISPR Therapeutics (CRSP) Buy Recommendation - MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Canal Insurance CO Purchases New Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG Slides Despite Bullish Wall Street - TipRanks
CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc. - MarketBeat
CRSP Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
CRISPR Therapeutics AG (CRSP) stock dips while market gains: Key facts - MSN
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts - Yahoo Finance
3 Reasons to Buy CRISPR Therapeutics Stock - The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - AOL.com
CRSP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $80 - GuruFocus
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
Crispr Therapeutics Ag (CRSP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 23 '26 |
Sale |
46.78 |
3,182 |
148,854 |
94,308 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 23 '26 |
Sale |
46.78 |
10,020 |
468,736 |
255,501 |
| Prasad Raju | Chief Financial Officer |
Mar 23 '26 |
Sale |
46.78 |
3,708 |
173,460 |
15,565 |
| Patel Naimish | Chief Medical Officer |
Mar 16 '26 |
Sale |
48.26 |
3,150 |
152,019 |
13,143 |
| Prasad Raju | Chief Financial Officer |
Mar 16 '26 |
Sale |
48.26 |
9,869 |
476,278 |
13,773 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 16 '26 |
Sale |
48.26 |
3,450 |
166,497 |
91,240 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 16 '26 |
Sale |
48.26 |
10,349 |
499,443 |
245,834 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '26 |
Sale |
52.80 |
2,800 |
147,840 |
87,815 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '26 |
Sale |
52.80 |
9,798 |
517,334 |
235,558 |
| Kulkarni Samarth | Chief Executive Officer |
Feb 19 '26 |
Sale |
52.58 |
6,967 |
366,325 |
226,106 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):